We are live on ! Find out more
IBIO icon

iBio
IBIO

9 hedge funds and large institutions have $581K invested in iBio in 2014 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0% less ownership

Funds ownership: 0% → 0% (-0%)

10% less funds holding

Funds holding: 10 → 9 (-1)

24% less capital invested

Capital invested by funds: $767K → $581K (-$186K)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
9
Holders Change
-1
Holders Change %
-10%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$26K
2
U
UBS
Switzerland
+$17.3K
3
CM
Churchill Management
California
+$8.65K
4
GHA
GW Henssler & Associates
Georgia
+$8.65K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$56K
2
VKH
Virtu KCG Holdings
New York
-$36K
3
Citigroup
Citigroup
New York
-$2.16K
4
Morgan Stanley
Morgan Stanley
New York
-$2.16K

IBIO Hedge Fund Activity: Q2 2014 in Review

9 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q2 2014, worth a combined $581K — down 24% from $767K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of IBIO and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.

The largest buyer was Vanguard Group, adding an estimated $26K. The largest seller was Citadel Advisors, exiting entirely with an estimated $56K sold.

  • 9 institutional investors held iBio (IBIO) as of Q2 2014, down from 10 in Q1 2014.
  • Funds reported $581K of iBio stock for Q2 2014, down 24% quarter-over-quarter.
  • 2 funds opened new iBio positions in Q2 2014 and 3 closed out, a net change of -1 holder.
  • The largest iBio buyer in Q2 2014 was Vanguard Group, an estimated $26K added.
  • The largest iBio seller in Q2 2014 was Citadel Advisors, an estimated $56K sold.

Based on aggregated 13F filings for Q2 2014.